Can you take Ixabepilone with Talquetamab?
1 drug interaction and 14 additional warnings found for the following 2 drugs:
- ixabepilone
- talquetamab
Drug interactions
Moderate drug interactions
Moderate:
ixabepilone talquetamab
Applies to: ixabepilone and talquetamab
Using ixabepilone together with talquetamab may increase the risk of nerve damage, which is a potential side effect of both medications.
Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications.
Let your doctor know if you develop weakness, numbness, pain, burning, or tingling in your hands, feet, or limbs.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
ixabepilone Food/Lifestyle
Applies to: ixabepilone
Do not consume grapefruit or grapefruit juice during treatment with ixabepilone unless specifically directed otherwise by your doctor.
Ixabepilone can interact with grapefruit and grapefruit juice and the interaction may increase the effects of ixabepilone.
You should discuss the use of grapefruit and grapefruit juice with your doctor.
Disease interactions
13 potential interactions Applies to: 12 conditions, including Peripheral Neuropathy, Arrhythmia, Diabetes Mellitus, Liver Disease, and Infection.
Arrhythmia
Moderate:
ixabepilone
Ixabepilone has a moderate potential interaction with Arrhythmia.
The use of ixabepilone in combination with capecitabine may increase cardiac adverse reactions, such as myocardial ischemia and ventricular dysfunction. Care should be exercised when using this agent in combination with capecitabine in patients with a history of cardiac disease. It is recommended to discontinue treatment in patients who develop cardiac ischemia or impaired cardiac function.
Cardiovascular Conditions and Disorders
Moderate:
ixabepilone
Ixabepilone has a moderate potential interaction with Cardiovascular Conditions and Disorders.
The use of ixabepilone in combination with capecitabine may increase cardiac adverse reactions, such as myocardial ischemia and ventricular dysfunction. Care should be exercised when using this agent in combination with capecitabine in patients with a history of cardiac disease. It is recommended to discontinue treatment in patients who develop cardiac ischemia or impaired cardiac function.
Diabetes Mellitus
Moderate:
ixabepilone
Ixabepilone has a moderate potential interaction with Diabetes Mellitus.
The use of ixabepilone in combination with capecitabine may cause peripheral neuropathy. Patients treated with ixabepilone in combination with capecitabine should be monitored for symptoms of neuropathy. Patients experiencing new or worsening symptoms may require a reduction or delay in the dose. Caution should be used when treating patients with diabetes mellitus or preexisting peripheral neuropathy.
Hyperbilirubinemia
Major:
ixabepilone
Ixabepilone has a major potential interaction with Hyperbilirubinemia.
The use of ixabepilone in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN due to increased risk of toxicity and neutropenia-related death.
Immunodeficiency
Major:
ixabepilone
Ixabepilone has a major potential interaction with Immunodeficiency.
Ixabepilone is contraindicated in patients who have a neutrophil count <1500 cells/mm3 or a platelet count <100,000 cells/mm3.
Infection
Moderate:
talquetamab
Talquetamab has a moderate potential interaction with Infection.
Teclistamab and talquetamab can cause severe, life-threatening, or fatal infections. Patients should be monitored for signs and symptoms of infection prior to and during treatment. Any infection should be treated appropriately. Administer prophylactic antimicrobials according to clinical guidelines.
Ischemic Heart Disease
Moderate:
ixabepilone
Ixabepilone has a moderate potential interaction with Ischemic Heart Disease.
The use of ixabepilone in combination with capecitabine may increase cardiac adverse reactions, such as myocardial ischemia and ventricular dysfunction. Care should be exercised when using this agent in combination with capecitabine in patients with a history of cardiac disease. It is recommended to discontinue treatment in patients who develop cardiac ischemia or impaired cardiac function.
Liver Disease
Major:
ixabepilone
Ixabepilone has a major potential interaction with Liver Disease.
The use of ixabepilone in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN due to increased risk of toxicity and neutropenia-related death.
Moderate:
talquetamab
Talquetamab has a moderate potential interaction with Liver Disease.
The effects of severe renal impairment (eGFR less than 30 mL/min) on the pharmacokinetics of teclistamab and talquetamab are unknown. Moderate to severe hepatic impairment (total bilirubin greater than 1.5 times ULN with any AST) on the pharmacokinetics of teclistamab are unknown. Severe hepatic impairment (total bilirubin greater than 3 times ULN with any AST) on the pharmacokinetics of talquetamab are unknown. Additionally, teclistamab and talquetamab have caused hepatotoxicity, including fatalities. Caution is advised in patients with renal and hepatic impairment. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated.
Neutropenia
Major:
ixabepilone
Ixabepilone has a major potential interaction with Neutropenia.
Ixabepilone is contraindicated in patients who have a neutrophil count <1500 cells/mm3 or a platelet count <100,000 cells/mm3.
Peripheral Neuropathy
Moderate:
ixabepilone
Ixabepilone has a moderate potential interaction with Peripheral Neuropathy.
The use of ixabepilone in combination with capecitabine may cause peripheral neuropathy. Patients treated with ixabepilone in combination with capecitabine should be monitored for symptoms of neuropathy. Patients experiencing new or worsening symptoms may require a reduction or delay in the dose. Caution should be used when treating patients with diabetes mellitus or preexisting peripheral neuropathy.
Renal Dysfunction
Moderate:
talquetamab
Talquetamab has a moderate potential interaction with Renal Dysfunction.
The effects of severe renal impairment (eGFR less than 30 mL/min) on the pharmacokinetics of teclistamab and talquetamab are unknown. Moderate to severe hepatic impairment (total bilirubin greater than 1.5 times ULN with any AST) on the pharmacokinetics of teclistamab are unknown. Severe hepatic impairment (total bilirubin greater than 3 times ULN with any AST) on the pharmacokinetics of talquetamab are unknown. Additionally, teclistamab and talquetamab have caused hepatotoxicity, including fatalities. Caution is advised in patients with renal and hepatic impairment. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated.
Thrombocytopenia
Major:
ixabepilone
Ixabepilone has a major potential interaction with Thrombocytopenia.
Ixabepilone is contraindicated in patients who have a neutrophil count <1500 cells/mm3 or a platelet count <100,000 cells/mm3.
Report options
More resources
ixabepilone
A total of 450 drugs are known to interact with ixabepilone.
- Ixabepilone is in the drug class mitotic inhibitors.
- Ixabepilone is used to treat the following conditions:
talquetamab
A total of 483 drugs are known to interact with talquetamab.
- Talquetamab is in the drug class bispecific T-cell engagers (BiTE).
- Talquetamab is used to treat Multiple Myeloma.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.